Search
Fexapotide
go.drugbank.com/drugs/DB05493InvestigationalNX-1207 is an investigational new drug for BPH, whose chemical entity and mechanism of action remain undisclosed. … Nymox Pharmaceutical Corporation recently completed studies of NX-1207 for treatment of benign prostatic hyperplasia (BPH).
Letrozole
go.drugbank.com/drugs/DB01006ApprovedInvestigationalLetrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.
Isopropyl myristate
go.drugbank.com/drugs/DB13966Approved[A178078] At the moment the primary usage for which isopropyl myristate is formally indicated is as the active ingredient in a non-prescription pediculicide rinse [A32333, L1964, L1966].
Uric acid
go.drugbank.com/drugs/DB08844InvestigationalAt present (August 2013), there is no approved formulation or indication for uric acid.
Categories: Compounds used in a research, industrial, or household settingTreprostinil
go.drugbank.com/drugs/DB00374ApprovedInvestigationalTreprostinil was approved by the FDA in 2002 for the treatment of pulmonary arterial hypertension. … The first generic form of treprostinil became available in 2019.[A248775]
Ibutilide
go.drugbank.com/drugs/DB00308ApprovedIt is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR).
BNT162a1 SARS-CoV-2 Vaccine
go.drugbank.com/drugs/DB15697Experimental[L15002, L15007] BNT162a1 is a uridine mRNA (uRNA) vaccine formulated in lipid nanoparticles for delivery via intramuscular injection. … BNT162a1 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.
Categories: Experimental Unapproved Treatments for COVID-19BNT162c2 SARS-CoV-2 Vaccine
go.drugbank.com/drugs/DB15698Experimental[L15002, L15007] BNT162c2 is a self-amplifying mRNA (saRNA) vaccine formulated in lipid nanoparticles for delivery via intramuscular injection. … BNT162c2 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.
Categories: Experimental Unapproved Treatments for COVID-19trans NV-04
go.drugbank.com/drugs/DB05843Experimentaltrans NV-04 is a cardiovascular drug which shows a significant reduction in blood pressure and arterial stiffness.
MK-0752
go.drugbank.com/drugs/DB12852InvestigationalMk 0752 is under investigation in clinical trial NCT00572182 (MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer).